<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370512</url>
  </required_header>
  <id_info>
    <org_study_id>10-008810</org_study_id>
    <nct_id>NCT01370512</nct_id>
  </id_info>
  <brief_title>Droxidopa / Pyridostigmine in Orthostatic Hypotension</brief_title>
  <official_title>Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural
      transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
      This combination should result in enhanced orthostatic release of NE. The investigators have
      already demonstrated that pyridostigmine does not raise supine blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the improvement in diastolic BP fall at the end of 5 minutes of standing.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine versus placebo on supine NE and its orthostatic increment.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine on orthostatic symptoms.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>Droxidopa / Pyridostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa</intervention_name>
    <description>100 mg t.i.d. for 2 days; then 200 mg t.i.d. for another 2 days</description>
    <arm_group_label>Droxidopa / Pyridostigmine</arm_group_label>
    <arm_group_label>Droxidopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine Bromide</intervention_name>
    <description>180 mg daily for 4 days</description>
    <arm_group_label>Droxidopa / Pyridostigmine</arm_group_label>
    <arm_group_label>Pyridostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. The presence of orthostatic hypotension (fall in systolic BP greater than or equal to
             30 mm Hg) is required for this study;

          2. Autonomic testing and clinical evaluation demonstrates OH to be of neurogenic
             etiology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tonette Gehrking</last_name>
    <phone>507-284-0336</phone>
    <email>adc.research@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonette Gehrking</last_name>
      <phone>507-284-0336</phone>
      <email>adc.research@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Phillip A. Low, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 12, 2016</lastchanged_date>
  <firstreceived_date>June 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Phillip Low</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
